About Agios Pharmaceuticals, Inc.
https://www.agios.comAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.
CEO
Brian M. Goff
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
B of A Securities
Buy
Leerink Partners
Outperform
Scotiabank
Sector Outperform
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:5.78M
Value:$166.09M
VANGUARD GROUP INC
Shares:5.6M
Value:$161.03M
BLACKROCK INC.
Shares:4.86M
Value:$139.6M
Summary
Showing Top 3 of 293
About Agios Pharmaceuticals, Inc.
https://www.agios.comAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.88M ▲ | $128.07M ▼ | $-103.43M ▲ | -803.05% ▲ | $-1.78 ▲ | $-102.06M ▲ |
| Q2-2025 | $12.46M ▲ | $136.55M ▲ | $-112.02M ▼ | -899.4% ▲ | $-1.93 ▼ | $-110.76M ▼ |
| Q1-2025 | $8.73M ▼ | $114.27M ▼ | $-89.29M ▲ | -1.02K% ▼ | $-1.55 ▲ | $-105.35M ▲ |
| Q4-2024 | $10.73M ▲ | $134.51M ▲ | $-96.52M ▼ | -899.56% ▼ | $-1.69 ▼ | $-123.67M ▼ |
| Q3-2024 | $8.96M | $110.99M | $947.91M | 10.57K% | $16.65 | $-101.47M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $952.86M ▲ | $1.39B ▼ | $101.38M ▼ | $1.28B ▼ |
| Q2-2025 | $938.94M ▲ | $1.47B ▼ | $101.68M ▲ | $1.37B ▼ |
| Q1-2025 | $893.38M ▼ | $1.56B ▼ | $88.99M ▼ | $1.47B ▼ |
| Q4-2024 | $893.71M ▼ | $1.66B ▼ | $122.24M ▼ | $1.54B ▼ |
| Q3-2024 | $1B | $1.79B | $165.12M | $1.63B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-103.43M ▲ | $-88.15M ▼ | $95.56M ▲ | $4.43M ▲ | $11.84M ▲ | $-89.71M ▼ |
| Q2-2025 | $-112.02M ▼ | $-77.12M ▲ | $78.97M ▼ | $65K ▼ | $1.91M ▼ | $-78M ▲ |
| Q1-2025 | $-89.29M ▲ | $-111.49M ▲ | $112.59M ▲ | $1.62M ▼ | $2.72M ▲ | $-112.25M ▲ |
| Q4-2024 | $-96.52M ▼ | $-133.17M ▼ | $-49.16M ▼ | $4.84M ▲ | $-177.48M ▼ | $-134.13M ▼ |
| Q3-2024 | $947.91M | $-84.22M | $250.79M | $2.64M | $169.21M | $-84.64M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Brian M. Goff
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
B of A Securities
Buy
Leerink Partners
Outperform
Scotiabank
Sector Outperform
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:5.78M
Value:$166.09M
VANGUARD GROUP INC
Shares:5.6M
Value:$161.03M
BLACKROCK INC.
Shares:4.86M
Value:$139.6M
Summary
Showing Top 3 of 293